Cargando…
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
BACKGROUND: Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA). METHODS: A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues fr...
Autores principales: | Komura, Kazumasa, Hirosuna, Kensuke, Tokushige, Satoshi, Tsujino, Takuya, Nishimura, Kazuki, Ishida, Mitsuaki, Hayashi, Takuo, Ura, Ayako, Ohno, Takaya, Yamazaki, Shogo, Nakamori, Keita, Kinoshita, Shoko, Maenosono, Ryoichi, Ajiro, Masahiko, Yoshikawa, Yuki, Takai, Tomoaki, Tsutsumi, Takeshi, Taniguchi, Kohei, Tanaka, Tomohito, Takahara, Kiyoshi, Konuma, Tsuyoshi, Inamoto, Teruo, Hirose, Yoshinobu, Ono, Fumihito, Shiraishi, Yuichi, Yoshimi, Akihide, Azuma, Haruhito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657138/ https://www.ncbi.nlm.nih.gov/pubmed/37980528 http://dx.doi.org/10.1186/s12943-023-01897-6 |
Ejemplares similares
-
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents
por: Komura, Kazumasa, et al.
Publicado: (2021) -
CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer
por: Tsujino, Takuya, et al.
Publicado: (2021) -
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
por: Nishimura, Kazuki, et al.
Publicado: (2022) -
Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan
por: Uchimoto, Taizo, et al.
Publicado: (2021) -
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021)